{"title":"Abstracts presented at the 2013 Annual Symposium of the Belgische Vereniging voor Klinische Chemie, Société Belge de Chimie Clinique.","authors":"","doi":"10.1179/0001551214Z.00000000067","DOIUrl":null,"url":null,"abstract":"s presented at the 2013 Annual Symposium of the Belgische Vereniging voor Klinische Chemie, Société Belge de Chimie Clinique ANNUAL SYMPOSIUM 2013 B1: Evaluation of the Roche cobas b101 pointof-care instrument for glycated hemoglobin testing in an ambulant hospital setting S. Jonckheere, M. Langlois AZ Sint-Jan Brugge-Oostende AV Background: Hemoglobin A1c (HbA1c) is currently used both for monitoring and diagnosing patients with diabetes mellitus. Point-of-care (POC) instruments have been proposed to improve the glycemic control of patients with diabetes by providing a rapid result if the analytical performance is acceptable. In this study, we evaluated the Roche cobas b101, a new HbA1c POC device. Methods: Precision was determined by testing both control material supplied by the manufacturer and patient blood samples. Accuracy was investigated by method comparison on 154 outpatients attending the diabetic clinic using two different lot numbers. Two certified secondary reference methods were used as comparator. Results: Total CV’s ranged from 2.4 to 7.4% using the NGSP units (%) and from 3.3 to 11.2% using the IFCC units (mmol/mol), respectively. A rather modest correlation (r50.934) and a clinically relevant negative bias of 25.75 mmol/mol (20.53%-DCCT) was observed between the cobas b101 and the mean of the secondary reference methods. Moreover, considerable lot number variability was noticed. Conclusions: The performance of the cobas b101 was insufficient according to the current quality specifications for HbA1c. We believe that both for monitoring and for diagnosis of diabetes, the cobas b101 POC device does not provide the quality needed. B2: Performance characteristics of faecal calprotectin testing for diagnosis of Inflammatory Bowel Disease M. Oyaert, C. Trouvé, F. Baert, D. De Smet, M. Langlois, H. Vanpoucke Clinical Laboratory, AZ Delta Roeselare-Menen, Department of Laboratory Medicine, AZ St-Jan Brugge Oostende, Department of Gastro Enterology, AZ Delta Roeselare Menen Acta Clinica Belgica 2014 DOI 10.1179/0001551214Z.00000000067 Acta Clinica Belgica 2014 VOL. 69 SUPPL 2 S2-","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1179/0001551214Z.00000000067","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Clinica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1179/0001551214Z.00000000067","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
s presented at the 2013 Annual Symposium of the Belgische Vereniging voor Klinische Chemie, Société Belge de Chimie Clinique ANNUAL SYMPOSIUM 2013 B1: Evaluation of the Roche cobas b101 pointof-care instrument for glycated hemoglobin testing in an ambulant hospital setting S. Jonckheere, M. Langlois AZ Sint-Jan Brugge-Oostende AV Background: Hemoglobin A1c (HbA1c) is currently used both for monitoring and diagnosing patients with diabetes mellitus. Point-of-care (POC) instruments have been proposed to improve the glycemic control of patients with diabetes by providing a rapid result if the analytical performance is acceptable. In this study, we evaluated the Roche cobas b101, a new HbA1c POC device. Methods: Precision was determined by testing both control material supplied by the manufacturer and patient blood samples. Accuracy was investigated by method comparison on 154 outpatients attending the diabetic clinic using two different lot numbers. Two certified secondary reference methods were used as comparator. Results: Total CV’s ranged from 2.4 to 7.4% using the NGSP units (%) and from 3.3 to 11.2% using the IFCC units (mmol/mol), respectively. A rather modest correlation (r50.934) and a clinically relevant negative bias of 25.75 mmol/mol (20.53%-DCCT) was observed between the cobas b101 and the mean of the secondary reference methods. Moreover, considerable lot number variability was noticed. Conclusions: The performance of the cobas b101 was insufficient according to the current quality specifications for HbA1c. We believe that both for monitoring and for diagnosis of diabetes, the cobas b101 POC device does not provide the quality needed. B2: Performance characteristics of faecal calprotectin testing for diagnosis of Inflammatory Bowel Disease M. Oyaert, C. Trouvé, F. Baert, D. De Smet, M. Langlois, H. Vanpoucke Clinical Laboratory, AZ Delta Roeselare-Menen, Department of Laboratory Medicine, AZ St-Jan Brugge Oostende, Department of Gastro Enterology, AZ Delta Roeselare Menen Acta Clinica Belgica 2014 DOI 10.1179/0001551214Z.00000000067 Acta Clinica Belgica 2014 VOL. 69 SUPPL 2 S2-
期刊介绍:
Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine primarily publishes papers on clinical medicine, clinical chemistry, pathology and molecular biology, provided they describe results which contribute to our understanding of clinical problems or describe new methods applicable to clinical investigation. Readership includes physicians, pathologists, pharmacists and physicians working in non-academic and academic hospitals, practicing internal medicine and its subspecialties.